Companies / ABBV

AbbVie Inc.

ABBV · Pharmaceutical Preparations · Fiscal year ends in December · CIK 0001551152
Revenue FY2026—
Net income—
Net margin—
Revenue growth since 2011—

Annual, in US dollars. Source: 10-K XBRL data.

11121314151617181920212258235424562561260
Fiscal yearFY2011 🔒FY2012 🔒FY2013 🔒FY2014 🔒FY2015 🔒FY2016 🔒FY2017 🔒FY2018 🔒FY2019 🔒FY2020 🔒FY2021 🔒FY2022FY2023FY2024FY2025FY2026
Revenue$0.4B$-239.6B$-2.5B$8.7B$-50.0M$16.5M$251.8B$16.9M$13.9M$34.4B$-106.3B$58.1B$54.3B$56.3B$61.2B—
Revenue growth—-56830.1%-99.0%-453.5%-100.6%-133.0%+1527401.8%-100.0%-17.8%+247936.9%-408.8%-154.6%-6.4%+3.7%+8.6%—
Gross profit————————————————
Operating income$-0.3B$16.3M$3.0B$5.5M$2.3B$45.0B$1.8B$323.6B$31.3M$10.9M$0.1B$18.1B$12.8B$9.1B$15.1B—
Net income———$0.1B$6.8M$0.6B$-43.8B$98.3B$71.0B$26.7B$15.0B$11.8B$4.9B$4.3B$4.2B—
Net margin———8.0%-2.6%37.0%31.4%-16.9%12.5%19.1%0.0%20.4%9.0%20.4%9.0%—
EPS (diluted)$11.50$9.83$8.52$9.08$8.08$-4.73$7.70$8.09$6.12$6.96$5.41$6.63$2.72$2.39$2.36—
P/E ratio——46.9×35.0×10.7×33.8×6.6×7.6×28.7×42.3×19.1×24.4×57.0×74.4×96.8×—
P/B ratio———8.3×24.4×19.9×14.6×42.4×14.8×14.0×15.1×16.6×26.5×94.4×n/m—

11 older years and all quarters are in Pro.

Daily closing prices, aggregated by calendar year.

1314151617181920212223242526
Year2013 🔒2014 🔒2015 🔒2016 🔒2017 🔒2018 🔒2019 🔒2020 🔒2021 🔒20222023202420252026 (YTD)
Open$378.61$18.34$449.84$304.76$338.73$133.37$466.23$519.36$337.29$135.74$162.28$154.89$178.78$228.74
Close$431.82$174.57$285.60$187.24$448.77$194.03$590.45$281.85$247.77$161.60$155.01$177.76$228.49$265.11
High$458.80$180.66$494.56$329.18$463.55$194.66$642.18$538.17$341.72$175.91$168.11$207.25$244.81$269.39
Low$344.01$17.37$259.90$187.18$321.90$124.54$458.31$268.13$237.98$128.27$130.98$153.58$164.41$191.33
Annual return-11.2%+26.3%-11.1%-15.3%+13.0%+4.3%-12.5%-27.2%-0.8%+19.3%-4.1%+14.7%+28.5%+16.0%

9 older years and daily export are in Pro.